Articles tagged with 'Press release' | BIOTRONIK

BIOTRONIK - Archive (Press release)

2020
17
September
2020
| 08:57 Europe/Amsterdam
Outcomes of the BIO4AMB trial presented at the CIRSE 2020 Summit demonstrated that ambulatory treatment with 4­‑French (4F) devices is a valid and safe option for endovascular treatment of lower extremity peripheral artery disease (PAD). The 4F compa...
Read more
07
September
2020
| 08:45 Europe/Amsterdam
BIOTRONIK today announced European market release of the Passeo®‑35 Xeo PTA (percutaneous transluminal angioplasty) balloon catheter. Compared to other available PTA balloons1, the device offers physicians improved crossability, excellent trackabilit...
Read more
01
September
2020
| 16:12 Europe/Amsterdam
A new study1 presented at this year’s European Society of Cardiology (ESC) Congress today shows that BIOTRONIK’s exclusive Closed Loop Stimulation (CLS) helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats. ...
Read more
01
September
2020
| 07:00 Europe/Amsterdam
Cardiologists balancing increasing workload pressures and time demands in their clinics, have from today access to a new injectable cardiac monitor (ICM). BIOMONITOR IIIm is equipped with a unique algorithm that significantly reduces false positive a...
Read more
14
July
2020
| 09:55 Europe/Amsterdam
BIOTRONIK is proud to announce the availability of its next-generation balloon-expandable cobalt chromium iliac stent system, Dynetic®-35. When compared to leading competitors, the new peripheral stent has up to 14 times greater flexibility and up to...
Read more
16
June
2020
| 12:50 Europe/Amsterdam
BIOTRONIK has today announced its commitment to giving physicians additional tools to pace in the His-Bundle, coinciding with the launch of its His-Bundle Pacing (HBP) tools in a limited number of centers starting now with a full launch later in 2020...
Read more
20
May
2020
| 16:00 Europe/Amsterdam
BIOTRONIK and Acutus Medical today announced a new alliance to provide a comprehensive portfolio of electrophysiology, mapping, ablation and accessory products for catheter-based treatment of cardiac arrhythmias across select markets, including Europ...
Read more
13
May
2020
| 13:30 Europe/Amsterdam
Results just published in Circulation Arrhythmia and Electrophysiology confirm that BIOTRONIK Home Monitoring® provides safe and cost-effective remote management of pacemaker patients,1 indicating that it can safely replace the common practice of rou...
Read more
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
24
February
2020
| 00:00 Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
21
February
2020
| 14:11 Europe/Amsterdam
BIOTRONIK has announced CE Mark certification for the Orsiro® Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents.1 Orsiro Mission is n...
Read more
27
January
2020
| 00:00 Europe/Amsterdam
BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer. Dr. Hayes will oversee the development of BIOTRONIK’s cardiovascular solutions with a focus on advancing unique, proven innovations that help physicia...
Read more
23
January
2020
| 00:00 Europe/Amsterdam
BIOTRONIK this month announced the market release of its new injectable cardiac monitor (ICM), BIOMONITOR III. The novel device is designed to help patients with irregular heart rhythms by documenting unexplained syncope with increased clarity. As...
Read more
2019
30
October
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients and physicians in t...
Read more
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
18
September
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced that it is the world’s first manufacturer to receive European Medical Device Regulation (MDR) certification for a Class III (highest risk) medical device. Following a successful conformity assessment, BIOTRONIK also obtained...
Read more
11
September
2019
| 00:00 Europe/Amsterdam
Twelve-month results of the BIOFLEX COF trial have demonstrated that the implantation of stents with low chronic outward force1 (COF) was associated with less neointimal hyperplasia2, consequently resulting in less restenosis. Patients treated with B...
Read more
02
September
2019
| 00:00 Europe/Amsterdam
BIOTRONIK’s ultrathin Orsiro® stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at 12 months, according to newly released data from the BIOSTEMI trial.1 Today Dr. Juan Fernando Iglesias, Geneva University Hospital...
Read more
31
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is used in emergency situations to create a physical b...
Read more
22
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the publication of the SENSE Trial results in the Journal of Cardiac Electrophysiology, proving BIOTRONIK’s DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate...
Read more
08
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatme...
Read more
28
June
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the market release of its new injectable cardiac monitor (ICM), BIOMONITOR III, following approval in the CE region. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhyth...
Read more
07
June
2019
| 00:00 Europe/Amsterdam
New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris®1 resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior Interventional Cardiologist at Antwerp Cardiovascul...
Read more
27
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that the first patient for the BIO|MASTER.Cor Family study was enrolled at Pauls Stradins Clinical University Hospital in Riga, Latvia at the cardiology department led by Prof. Andrejs Erglis. The patient received a Rivacor ...
Read more
21
May
2019
| 00:00 Europe/Amsterdam
Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion revascularization (TLR) rate and thus better efficacy of the Orsiro® drug-eluting stent1 (DES)...
Read more
08
May
2019
| 00:00 Europe/Amsterdam
Heartbeat International (HBI) Foundation President Dr. Benedict S. Maniscalco will be honored with the Heart Rhythm Society (HRS) Global Humanitarian Award at this year’s Scientific Sessions. Dr. Maniscalco, the first-ever recipient of this award, is...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device t...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
The observational THORN registry1 highlights the importance of rapid corrective action by medical staff in cases of inappropriate diagnosis and therapy using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibri...
Read more
29
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today the availability of its Plexa ProMRI S DX lead, with DF4/IS-1 connector in Europe and the US. The lead is an extension of BIOTRONIK’s Plexa family. Together with the new lead and recently launched Acticor/Rivacor ICD and CRT...
Read more
29
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defi...
Read more